GenVault

About GenVault

GenVault, a subsidiary of Brooks Life Sciences, specializes in the secure storage and management of biological samples and genetic material. The company was originally founded in 2002 to address the growing need for reliable room-temperature biosample storage solutions, a critical component for the genomics and life sciences research markets. In 2011, GenVault was acquired by IntegenX, a developer of rapid DNA identification technology. This acquisition was followed by the subsequent acquisition of IntegenX by Thermo Fisher Scientific in 2018. Throughout these transitions, GenVault has maintained its focus on providing a comprehensive suite of products and services centered around its core room-temperature storage technology.

The company's business model is anchored in providing a more cost-effective and space-efficient alternative to traditional cold storage freezer farms. GenVault's systems are designed to preserve the integrity of DNA and RNA samples at ambient temperatures, which significantly reduces the financial and environmental costs associated with energy consumption and freezer maintenance. This approach caters to a diverse client base, including academic research institutions, pharmaceutical companies, biobanks, and clinical diagnostic laboratories that handle large volumes of biospecimens for research, drug discovery, and diagnostics.

GenVault's product portfolio includes chemically treated papers and plates for sample collection and storage, along with automated systems for sample handling, archiving, and retrieval. A key feature of their offering is the ability to stabilize nucleic acids for long-term preservation without the need for refrigeration, protecting valuable biological assets from degradation and potential power failures. This technology ensures sample viability for future analysis, which is crucial for longitudinal studies and the development of personalized medicine.